Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer
Status:
Completed
Trial end date:
2008-07-13
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the bioequivalence of the test product
Hospira Iron Sucrose 20 mg/mL (Hospira, Inc.) to the reference product Venofer® 20 mg/mL
following intravenous administration to healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer